| 2026-08-06 | 10-Q | 10.40 | Project Addendum for Development Services between Arcturus Therapeutics, Inc. and Patheon UK Limited, dated June 26, 2026. |
|---|
| 2026-08-06 | 10-Q | 10.39 | Master Services Agreement between Arcturus Therapeutics, Inc. and Thermo Fisher Scientific Inc., dated June 26, 2026. |
|---|
| 2026-05-07 | 8-K | 10.1 | Employment Agreement between Arcturus Therapeutics Holdings Inc. and Dennis Mulroy dated as of April 27, 2026. |
|---|
| 2025-12-15 | 8-K | 10.2 | Employment Agreement between Arcturus Therapeutics Holdings Inc. and Joe Roberts dated July 3, 2018. |
|---|
| 2025-12-15 | 8-K | 10.1 | Separation Agreement and General Release between Arcturus Therapeutics Holdings Inc. and Andy Sassine dated 11, 2025. |
|---|
| 2025-05-12 | 10-Q | 10.36 | Cost Reimbursement Contract dated August 31, 2022, by and between Arcturus Therapeutics Holdings Inc. and Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. Incorporated by reference to Exhibit 10.36 to Quarterly Report on Form 10-Q filed on November 9, 2022 (File No. 001-38942). |
|---|
| 2024-11-07 | 10-Q | 10.36 | Cost Reimbursement Contract dated August 31, 2022, by and between Arcturus Therapeutics Holdings Inc. and Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. Incorporated by reference to Exhibit 10.36 to Quarterly Report on Form 10-Q filed on November 9, 2022 (File No. 001-38942). |
|---|
| 2024-08-05 | 10-Q | 10.35 | First Amendment to Credit Agreement and First Amendment to Revolving Line of Credit, dated June 26, 2024, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. |
|---|
| 2024-06-14 | 8-K | 10.1 | Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended |
|---|
| 2024-05-08 | 10-Q | 10.33 | Amendment Number Two to Collaboration and License Agreement, dated March 29, 2024, by and between Arcturus Therapeutics, Inc. and Seqirus Inc. |
|---|
| 2023-11-14 | 10-Q | 10.32 | Amendment No. 4 to Letter Agreement, dated September 25, 2023, by and between Arcturus Therapeutics, Inc. and the Cystic Fibrosis Foundation. |
|---|
| 2023-11-14 | 10-Q | 10.31 | Amendment Number One to Collaboration and License Agreement, dated August 3, 2023, by and between Arcturus Therapeutics, Inc. and Seqirus Inc. |
|---|
| 2023-08-07 | 10-Q | 10.30 | Revolving Line of Credit Note dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.30 to Quarterly Report on Form 10-Q filed on May 9, 2023 (File No. 001-38942). |
|---|
| 2023-08-07 | 10-Q | 10.29 | Security Agreement dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.29 to Quarterly Report on Form 10-Q filed on May 9, 2023 (File No. 001-38942). |
|---|
| 2023-08-07 | 10-Q | 10.28 | Credit Agreement dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.28 to Quarterly Report on Form 10-Q filed on May 9, 2023 (File No. 001-38942). |
|---|
| 2023-05-09 | 10-Q | 10.30 | Revolving Line of Credit Note dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. |
|---|
| 2023-05-09 | 10-Q | 10.29 | Security Agreement dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. |
|---|
| 2023-05-09 | 10-Q | 10.28 | Credit Agreement dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. |
|---|
| 2023-03-29 | 10-K | 10.41 | Manufacturing Support Agreement Termination Letter, dated March 23, 2023, by and between Arcturus Therapeutics, Inc. and the Economic Development of Singapore. |
|---|
| 2022-11-09 | 10-Q | 10.38 | Collaboration and License Agreement, dated November 1, 2022, by and between Arcturus Therapeutics Holdings Inc. and CSL Limited. |
|---|
| 2022-11-09 | 10-Q | 10.36 | Sixth Amendment to Loan and Security Agreement, dated April 19, 2022, by and between Arcturus Therapeutics, Inc. and Western Alliance Bank. Incorporated by reference to Exhibit 10.36 to Form 10-Q filed on May 8, 2022 (File No. 001-38942). |
|---|
| 2022-11-04 | 8-K | 10.1 | Study Support Agreement effective October 31, 2022 by and between Arcturus Therapeutics, Inc. and Vinbiocare Biotechnology Joint Stock Company. |
|---|
| 2022-06-24 | 8-K | 10.1 | Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended |
|---|
| 2022-05-09 | 10-Q | 10.36 | Sixth Amendment to Loan and Security Agreement, dated April 19, 2022, by and between Arcturus Therapeutics, Inc. and Western Alliance Bank. |
|---|
| 2021-11-09 | 10-Q | 10.35 | Lease, by and between Arcturus Therapeutics, Inc. and TPSC IX, LLC, dated September 29, 2021. |
|---|
| 2021-11-09 | 10-Q | 10.34 | Fifth Amendment to Loan and Security Agreement, dated October 27, 2021, by and between Arcturus Therapeutics, Inc. and Western Alliance Bank. |
|---|
| 2021-08-10 | 10-Q | 10.33 | Framework Drug Substance Supply Agreement, signed July 29, 2021 and effective July 30, 2021, by and between Arcturus Therapeutics, Inc. and Vinbiocare Biotechnology Joint Stock Company. |
|---|
| 2021-08-10 | 10-Q | 10.32 | Technology License and Technical Support Agreement, signed July 29, 2021 and effective July 30, 2021, by and between Arcturus Therapeutics, Inc. and Vinbiocare Biotechnology Joint Stock Company. |
|---|
| 2021-04-26 | 8-K | 10.1 | Arcturus Therapeutics Holdings Inc. Severance Policy for Executives |
|---|
| 2021-03-01 | 10-K | 10.30 | Third Amendment to Lease, by and between Arcturus Therapeutics, Inc. and ARE-SD Region No. 44, LLC, dated February 25, 2021. |
|---|
| 2021-03-01 | 10-K | 10.29 | Second Amendment to Lease, by and between Arcturus Therapeutics, Inc. and ARE-SD Region No. 44, LLC, dated November 13, 2020. |
|---|
| 2020-12-07 | 8-K | 10.1 | Fourth Amendment to Loan and Security Agreement, dated December 1, 2020 |
|---|
| 2020-11-09 | 10-Q | 10.33 | Manufacturing Support Agreement, dated November 7, 2020, between Arcturus Therapeutics Holdings, Inc. and the Economic Development Board of Singapore. |
|---|
| 2020-11-09 | 10-Q | 10.32 | Supply Agreement, dated August 17, 2020, between Arcturus Therapeutics, Inc. and the Israeli Ministry of Health. |
|---|
| 2020-03-27 | 8-K | 10.1 | Sales Agreement, dated as of March 27, 2020, between the Company and Stifel, Nicolaus & Company, Incorporated |
|---|
| 2020-03-16 | 10-K | 10.24 | Acceptance Letter, dated March 4, 2020, between Arcturus Therapeutics Holdings Inc. and the Economic Development Board of Singapore. |
|---|
| 2020-03-16 | 10-K | 10.23 | Lease Agreement, by and between Arcturus Therapeutics Holdings Inc. and ARE-SD Region No. 44, LLC dated February 1, 2020. |
|---|
| 2020-03-16 | 10-K | 10.1 | Form of Indemnification Agreement. |
|---|
| 2019-11-08 | 10-Q | 10.25 | Third Amendment, dated October 30, 2019, by and between Western Alliance Bank, and Arcturus Therapeutics, Inc. to the Loan and Security Agreement dated as of October 12, 2018. |
|---|
| 2019-09-27 | 8-K | 10.1 | Form of Securities Purchase Agreement, dated September 25, 2019, between the Company and the purchasers party thereto |
|---|
| 2019-08-14 | 10-Q | 10.21 | Termination Agreement, dated July 26, 2019, by and between Arcturus Therapeutics, Inc. and CureVac AG. |
|---|
| 2019-08-14 | 10-Q | 10.20 | Amendment to Development and Option Agreement, dated July 26, 2019, by and between Arcturus Therapeutics, Inc. and CureVac AG. |
|---|
| 2019-08-14 | 10-Q | 10.16 | Amendment dated as of August 1, 2019, by and between Arcturus Therapeutics, Inc. and Cystic Fibrosis Foundation to that certain Development Program Letter Agreement of May 16, 2017. |
|---|
| 2019-08-05 | 8-K | 10.1 | Securities Purchase Agreement, dated August 2, 2019, between the Company and the Investor. |
|---|
| 2019-08-02 | 8-K | 10.1 | Securities Purchase Agreement, dated August 1, 2019, between the Company and the Investors party thereto |
|---|